Neuraxis appoints Dr. Gil Aharon to board effective Jan 1, 2025

Neuraxis, INC

Dr. Gil Aharon appointed to Neuraxis board effective Jan 1, 2025, as designee of investors in recent $5M Series B financing.
Dr. Aharon co-founded Rosalind Advisors and purchased $250,000 of Series B Convertible Preferred Stock in the transaction.
He has not yet been assigned to any board committee; director compensation is undetermined.
No family relationships with other directors or officers; no other material interests in related-party transactions.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Dr. Gil Aharon

Director

NRXS · Neuraxis, INC

Effective: 2025-01-01
Filed: November 25, 2024, 6:59 PM ET

the Board appointed Dr. Aharon to the Board, effective January 1, 2025.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Dr. Gil Aharon was appointed as Director at Neuraxis, INC.

Action: appointed
Role: Director

Exact text from the filing

the Board appointed Dr. Aharon to the Board, effective January 1, 2025.

View on SEC.gov

Neuraxis, INC filing history →

Source: SEC EDGAR

accession 0001493152-24-047623

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.